istock-625061004_warchicompliance
Warchi /iStockphoto.com
6 November 2017Americas

Pay-for-delay settlements fall for second year: FTC report

Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
13 March 2018   The number of ‘pay-for-delay’ patent settlements in the EU has “stabilised at a low level”, according to the European Commission.
Americas
1 March 2019   The US Federal Trade Commission concluded a ten-year pay-for-delay suit yesterday, with AbbVie agreeing not to enter certain settlements in patent cases that delay market entry of generic drugs.
Big Pharma
24 May 2019   The number of ‘pay-for-delay’ patent settlements reached in fiscal year 2016 represented a “considerable increase” from the previous year, according to a Federal Trade Commission report released yesterday, May 23, though there has been a considerable reduction in the most problematic settlements since 2013.

More on this story

Europe
13 March 2018   The number of ‘pay-for-delay’ patent settlements in the EU has “stabilised at a low level”, according to the European Commission.
Americas
1 March 2019   The US Federal Trade Commission concluded a ten-year pay-for-delay suit yesterday, with AbbVie agreeing not to enter certain settlements in patent cases that delay market entry of generic drugs.
Big Pharma
24 May 2019   The number of ‘pay-for-delay’ patent settlements reached in fiscal year 2016 represented a “considerable increase” from the previous year, according to a Federal Trade Commission report released yesterday, May 23, though there has been a considerable reduction in the most problematic settlements since 2013.

More on this story

Europe
13 March 2018   The number of ‘pay-for-delay’ patent settlements in the EU has “stabilised at a low level”, according to the European Commission.
Americas
1 March 2019   The US Federal Trade Commission concluded a ten-year pay-for-delay suit yesterday, with AbbVie agreeing not to enter certain settlements in patent cases that delay market entry of generic drugs.
Big Pharma
24 May 2019   The number of ‘pay-for-delay’ patent settlements reached in fiscal year 2016 represented a “considerable increase” from the previous year, according to a Federal Trade Commission report released yesterday, May 23, though there has been a considerable reduction in the most problematic settlements since 2013.